Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.50
Bid: 38.00
Ask: 39.00
Change: -2.00 (-4.94%)
Spread: 1.00 (2.632%)
Open: 40.50
High: 40.50
Low: 38.50
Prev. Close: 40.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Second Portuguese spin out: Des Solutio

30 Oct 2018 07:00

RNS Number : 5786F
Frontier IP Group plc
30 October 2018
 

30 October 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Second Portuguese spin out Des Solutio to develop green chemistry for beauty, pharmaceutical and food industries

 

Frontier IP, a specialist in commercialising university intellectual property, today announces it is taking a 25 per cent. stake in Des Solutio (the "Company"), a company developing safer and greener alternatives to the chemicals currently used to make beauty, pharmaceutical, personal care and other products.

 

The Company has been established to develop and commercialise the research of Associate Professor Ana Rita Duarte and Dr Alexandre Paiva, of Portugal's NOVA University Lisbon, NOVA School of Science and Technology ("FCT NOVA").

 

Their research has already attracted interest from several major industrial groups, including a world-leading cosmetics company and a major pharmaceutical company. In return for its stake, Frontier IP will provide Des Solutio with a broad range of commercialisation services, including contract negotiation and identifying and working with potential industry partners to validate and scale up the technology.

 

Des Solutio is developing new methods to use Natural Deep Eutectic Solvents ("NADES") in cosmetics, nutraceuticals and other applications, to replace toxic organic solvents, such as ethanol, employed currently. Solvents are commonly used in a wide range of industries to extract active ingredients from natural matrices, such as olive oil, mint or seaweed to flavour and scent their products, and enhance the shelf-life and stability of the bioactives.

 

NADES offer many benefits over existing solvents. Found in a vast range of plants, and so compliant with a green chemistry philosophy, they are entirely derived from natural compounds such as organic acids, amino acids and sugars.

 

As there are a vast range of NADES already identified, they can be matched to specific active ingredients to extract only what is needed. There is no need to recover an active ingredient from a NADES, unlike conventional solvents, some of which are too toxic for use on skin or in foods.

 

Other advantages of the technology include improved solubility, permeability and bioavailability of the active compounds, better biodegradability than many organic solvents and greener production processes.

 

The incorporation of Des Solutio is a further sign of Frontier IP's growing momentum in Portugal. It is the Group's second spin out from FCT NOVA following NTPE, a company developing novel technology to print electronic circuits, sensors and semiconductors on to paper. The Group recently entered into a strategic partnership with the UK government's Department for International Trade in Portugal.

 

Des Solutio co-founder, Associate Professor Ana Rita Duarte said:  "We're delighted to be working with Frontier IP on developing and bringing this ground-breaking science into the commercial world. NADES have huge potential for making a host of everyday products greener and saferfor people to use."

 

Frontier IP chief executive Neil Crabb said: "We're very excited about the possibilities for Des Solutio. The technology being developed by Professor Ana Rita Duarte and Dr Alexandre Paiva has already attracted interest from major multinationals. Its incorporation as our second Portuguese spin out is further sign of our growing strength in the country."

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers (Corporate Finance)

Amrit Nahal (Equity Sales)

 

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABLBDGBGDBGIC
Date   Source Headline
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights
25th Nov 20222:23 pmRNSDirector/PDMR Shareholding
23rd Nov 20225:17 pmRNSDirector share transfers
18th Nov 20223:53 pmRNSExercise of Options & PDMR Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.